As many products come off patent, this is causing ‘game-changing' falls in revenues. Consequently, industry is grappling with questions pertaining to the most effective strategies for developing meaningful new drugs and how it should collectively fund and reward their discovery and development activities.

Gone are the days that pharma companies can 'go it alone'. As a result, companies in the life sciences sector must think creatively in order to gain maximum potential and benefits from their partnering and collaboration strategies and models.

Following on from a portfolio of successful pharmaceutical events, SMi are proud to present their European Bionetwork Summit, Monday 7th – Tuesday 8th July, 2014, Central London. This important and timely meeting will allow biotech, pharma, academic and funding organisations to evaluate how they partner with other stakeholders in the field to accelerate research and reduce costs.

Join us and hear timely case studies, presentations, roundtables and panel discussions on the hottest topics, from leading experts as they demonstrate how to create winning strategic partnerships from modern day collaborations!

 Key Topics will discuss the key milestones involved and what you need to know before, during and after the partnering process including......

• The 4 musketeers… pharma, biotech, academia and venture capitalists! Taking advantage of each other’s strengths to drive drug discovery and R&D
Aligning pharma and venture capitalists… Reviewing how this is impacting on early stage investment
Funding for the future – where is the money right now and where is it heading?
• Positioning your organisation to win new deals by introducing alliance management tools
Dealmaking tips – working through the timeline for creating successful partnerships

This 2 day networking event will invite in depth discussion of key drivers impacting pharma, biotech, funding and academic partnerships providing a fantastic opportunity to hear from and talk to professionals currently operating in the market. Join the event of the year to:






• Hear cutting edging presentations and key cases studies from leading industry and academic experts
• Network and learn from your future partners
• Learn about the latest developments pertaining to strategic partnering and funding
• Discover how to showcase your strengths to grow your market share potential

SVPs, VPs, Heads and Directors of Pharma, Biotech, VC, Academia, Discovery Organisations involved in:

• Business Development
• Corporate Development
• New Deal Strategy and Development
• Strategic Partnerships
• Strategic Planning
• Licensing and External Research
• New Growth Opportunities
• Strategic Research Partnerships
• Intellectual Property
• Strategy and Operations
• Competitive Intelligence
• Business Intelligence
• Information Specialist
• Commercial/Customer Insights
• Strategic Planning
• Market/Marketing Research
• Decision Analysis/Decision Support
• Business Analytics
• New Product Planning/Development
• Forecasting
• Business Portfolio Planning
• Strategic/Business Analysis
• Business Development
• Portfolio Management/Planning
• Project Management
• Risk Management
• Research Planning
• Research & Development
• Regulatory
• Scientist
• Legal/Regulatory
• Outsourcing
• Manufacturing


Actelion Ltd. ; Asterand plc; Aston University; Barts Cancer Institute; Bayer; Bayer A G; BBI Solutions; Biogelx Ltd; Biopharm Insight; Charles University in Prague; Chondro Engineering AS; Durham Veterans Affairs Medical Center; GlaxoSmithKline; GSK; GSK R&D; Imagen Biotech; Imperial College London; INSERM U634; InSphero; Insphero A G; Karolinska Institute; King’s College London; Loughborough University; MedImmune; Rottapharm; Saarland University; St George's, University of London; St. George's, University of London; TAP Biosystems; Trinity College Dublin; UCB Pharmaceuticals Limited; UCL Institute of Liver and Digestive Health; University College London; University of Hertfordshire; University Of Sheffield; Wellcome Trust Functional Genomics Cell Bank;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Sanj Singh

Sanj Singh, President & CEO, AdeTherapeutics Inc

9:10 Looking at the crystal ball… scenario development for enhanced business development and licensing strategies

Mika Partanen

Mika Partanen, Deputy Director, Global Competitive Insights, Bayer Pharma

• Developing  a clear understanding of why the scope and the time frame for business development activities is the key first step in scenario development
• Avoiding corporate blind spots by involving outsiders in the identification/prioritization of key business development-related uncertainties and leading indicators
• Understanding why scenario development is not an exact science: judgment may sometimes beat complex analytical models and techniques, especially when time frames are tight
• Updating scenarios on a regular basis and establishing an early opportunity identification system

9:50 Going back to school… introducing academic partnerships as the way forward

Robert Williams

Robert Williams, Chief Development Scientist, Drug Development Office, Cancer Research UK

• Understanding why discovery and early stage drug development collaborations with academia are more popular than ever
• Risk sharing in drug development – a ‘not for profit’ perspective
• Scientific, technical and business challenges in cross sector collaboration

10:30 Morning Coffee

11:00 The new innovation kettle – a biotech perspective

Jorgen Drejer

Jorgen Drejer, Chief Executive Officer, Saniona

• New deal structures for innovation in drug discovery
• Maximising innovation and productivity in partnerships
• Expected trends for drug discovery business models:
• Venture capitalist, government funding, pharma partnering, spin out, joint ventures



11:40 Rx to OTC Switches: The Nexium Deal

Ian  Kirk

Ian Kirk, Transaction Director, Business Development, AstraZeneca

• The Over The Counter (OTC) market represents a significant opportunity for Life Cycle Management (LCM)
• The presentation will walk through the considerations and key factors influencing the decision by AstraZeneca to partner Nexium for OTC
• It will also cover some of the key learning that may be applicable to other companies wanting to evaluate OTC opportunities  

12:20 Networking Lunch

13:20 When alliances don’t work out – addressing the issues and developing solutions

Dimitri Dimitriou

Dimitri Dimitriou, Chief Executive Officer, ImmuPharma, & Managing Partner, DyoDelta Biosciences

• Choosing a partner with a higher probability of alignment on the key deal points
• At the outset of the partnership – contractual preparation for all potential outcomes
• Identifying and managing issues as they happen
• After the breakup

14:00 To pay or not to pay… that is the question!

Sanj Singh

Sanj Singh, President & CEO, AdeTherapeutics Inc

• Understanding how to develop successful pricing and reimbursement strategies – considering the ethical challenges
• Analysing  trends in pricing and use of health technology assessment for reimbursement decision making
• Understanding how to successfully secure reimbursement
• Reviewing current drug pricing policies
• The big question – does the industry need a different way of thinking about reimbursement requirements?

14:40 Afternoon Tea

15:10 ‘Fear no more the heat of the sun’…four ways to tackle reimbursement in emerging markets

Andreas  Guhl

Andreas Guhl , Founder , ValueMAxess Ltd

• Reviewing the implications for market growth and business development
• Monitoring how healthcare systems in emerging markets (China, India, Brazil, Russia, Mexico and Turkey) are evolving
• Exploring how this is impacting on the expected growth of markets for innovative companies at home
• Reviewing the prospects for drug and business development for these markets

15:50 The 4 musketeers…‘one for all and all for one’ – how can pharma, biotech, academia and venture capitalists live by this motto!

• Reviewing the various collaboration opportunities to increase R&D and innovation
• Seeking out partners with complementary strengths to lead innovation
• Creating a flexible, independent and lean structure amongst partners that allows for rapid decision making
• Maximizing the potential gains from successful  R&D and business development relationships
• Understanding how to mitigate the risks of partnering to:
o maximize ROI
o boost creativity

Lubor Gaal

Lubor Gaal, Head of Europe, Business Development, Bristol-myers Squibb

Jorgen Drejer

Jorgen Drejer, Chief Executive Officer, Saniona

Robert Williams

Robert Williams, Chief Development Scientist, Drug Development Office, Cancer Research UK

Sofia Ioannidou

Sofia Ioannidou, Investment Director, Edmond de Rothschild Investment Partners

16:50 Chairman’s Closing Remarks and Close of Day One

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Sanj Singh

Sanj Singh, President & CEO, AdeTherapeutics Inc

9:10 Biomarker-pharma partnering - an ideal partnership ?

Mark  Eccleston

Mark Eccleston, External Collaborations Manager, Volition RX

• Understanding the impact of early diagnosis/prognosis on clinical decisions
• Pinpointing opportunities for biomarker integration into discovery, preclinical and clinical development
• Cdx as enabling technology not restricting market
• Introducing surrogate biomarkers for efficacy monitoring/therapy switching in the clinical testing and application market



9:50 Trends in academic-industry collaborations

Amy Lam

Amy Lam, Acting Head, Business Development , Edinburgh bioQuarter

• Identifying the recent trends that we have observed in academic/industry collaborations
• Understanding what the academic medical centers are hoping to achieve from these collaborations
• What are the benefits to each of the partners?

10:30 Morning Coffee

11:00 Introducing open innovation to facilitate R&D success

Michael Meyers

Michael Meyers, Vice President of Scientific Innovation, Oncology, Johnson And Johnson

• Examining current open innovation business models being employed
• Reviewing the advantages of this novel discipline
• Recognizing how alliance management is a key contributor to the success of open innovation collaborations

11:40 The big question! - how to get noticed by the big league players

Lubor Gaal

Lubor Gaal, Head of Europe, Business Development, Bristol-myers Squibb

• What does a small/medium pharma-biotech need to do to get on "Big Pharma's" radar?
• What will this mean for the company
• Case study

12:20 Networking Lunch

13:20 The state, the private investor and the early stage bioentrepreneur

Davidson  Ateh

Davidson Ateh, Chief Executive Officer, BioMoti

14:00 Where and how are licensee’s & acquirers spending their money? An overview of deal trends, structures and deal values

Adrian Dawkes

Adrian Dawkes, Vice President, PharmaVentures

• How do the deals Big Pharma have been doing signal their strategic Intent
• Are option deals becoming more important as less upfront cash is risked
• When is a licensing deal really an M&A deal
• What is the optimum time in the development path to do your deal

14:40 Afternoon Tea

15:10 Structure based molecular design approaches in the development of small molecules leads

Colin Fishwick

Colin Fishwick, Head of Organic Chemistry, School of Chemistry, University of Leeds

•         Discussing our approach to fragment based in silico modeling
•         Setting up a cross departmental drug discovery platform: bringing clinicians and biologists together
•         Leveraging internal partnerships and collaborations to accelerate drug design

15:50 Enabling next generation PCR

Eddie Blair

Eddie Blair, Chief Executive Officer, GeneFirst Ltd

16:30 Chairman’s Closing Remarks and Close of Day Two


Marriott Regents Park

128 King Henry's Road
London NW3 3ST
United Kingdom

Marriott Regents Park

This 4 star north London hotel in zone 2 is the perfect destination for the astute business traveler as well as the leisure guest that knows how convenient north London hotels are, as a base from which to explore the city .Bond Street is just 3 stops from Swiss Cottage underground station on the Jubilee Line, so you can be shopping, exploring the sights and taking in one of London’s world-renowned West End shows in less than 15 minutes when you stay at this hotel near central London. At the same time, the hive of activity that is Camden Town, the chic shops, cafes and restaurants of Primrose Hill and ZSL’s London Zoo in Regents Park are all just a short walk from this hotel in north London.



speaker image






CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.


There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.


Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.


Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

Event Title


Read More

I would like to speak at an event

I would like to attend an event

I would like to sponsor/exhibit at an event


Sign up
Forgotten Password?


UK Office
Opening Hours: 9.00 - 17.30 (local time)
SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
Registered in England No: 3779287 VAT No: GB 976 2951 71

Forgotten Password

Please enter the email address you registered with. We will email you a new password.

Thank you for visiting our event

If you would like to receive further information about our events, please fill out the information below.

By ticking above you are consenting to receive information by email from SMi.
Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out